---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-032831"
form_type: "8-K"
ticker: "RTGN"
cik: "0001836295"
company_name: "RetinalGenix Technologies Inc."
filed_at: "2021-12-30T23:59:59+00:00"
generated_at: "2026-06-27T21:45:42.206803+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RetinalGenix exchanges 28M shares for pre-funded warrant; outstanding shares drop to 14.2M

## Summary
- Exchanged 28,014,540 shares held by Sanovas Ophth for a pre-funded warrant to purchase same number of shares at $0.0001 per share.
- Outstanding shares reduced from ~42.2M to 14,166,114 after cancellation of exchanged shares.
- Transaction with related party: CEO Jerry Katzman is sole manager of Sanovas Ophth.
- Warrant is immediately exercisable and terminates when exercised in full; no new cash received.
- Issued under Section 3(a)(9) exemption; no additional consideration was paid.

## SEC filing metadata
- accession: 0001493152-21-032831
- form_type: 8-K
- ticker: RTGN
- cik: 0001836295
- company_name: RetinalGenix Technologies Inc.
- filed_at: 2021-12-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1836295/000149315221032831/0001493152-21-032831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1836295/000149315221032831/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-032831
- JSON: https://secwatch.observer/filing/0001493152-21-032831.json
- Plain text: https://secwatch.observer/filing/0001493152-21-032831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.